famotidine has been researched along with Cystic Fibrosis in 4 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine pharmacokinetics were studied in 13 patients with severe cystic fibrosis (CF) ranging from 10 to 47 years of age and 25 to 72 kg in weight." | 9.08 | Pharmacokinetics of famotidine in patients with cystic fibrosis. ( Farrar, HC; Kearns, GL; Letzig, LG; Maish, WA; McCubbin, MM, 1998) |
| " We carried out a long-term prospective study in an attempt to clarify the effectiveness of the associated use of famotidine to enzymatic supplementation on fat absorption and nutritional parameters of patients with pancreatic insufficiency due to cystic fibrosis." | 9.07 | Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis. ( Averna, MR; Carroccio, A; Iacono, G; Iapichino, L; Montalto, G; Notarbartolo, A; Pardo, F; Soresi, M, 1992) |
| "Famotidine pharmacokinetics were studied in 13 patients with severe cystic fibrosis (CF) ranging from 10 to 47 years of age and 25 to 72 kg in weight." | 5.08 | Pharmacokinetics of famotidine in patients with cystic fibrosis. ( Farrar, HC; Kearns, GL; Letzig, LG; Maish, WA; McCubbin, MM, 1998) |
| " We carried out a long-term prospective study in an attempt to clarify the effectiveness of the associated use of famotidine to enzymatic supplementation on fat absorption and nutritional parameters of patients with pancreatic insufficiency due to cystic fibrosis." | 5.07 | Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis. ( Averna, MR; Carroccio, A; Iacono, G; Iapichino, L; Montalto, G; Notarbartolo, A; Pardo, F; Soresi, M, 1992) |
| " Dosage requirements vary according to age and clinical condition, and children require a relatively higher drug dosage (mg/kg) than adults." | 2.39 | Do H2 receptor antagonists have a therapeutic role in childhood? ( Kelly, DA, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Foer, D | 1 |
| Marquis, K | 1 |
| Romero, N | 1 |
| Castells, MC | 1 |
| Kelly, DA | 1 |
| Maish, WA | 1 |
| McCubbin, MM | 1 |
| Letzig, LG | 1 |
| Farrar, HC | 1 |
| Kearns, GL | 1 |
| Carroccio, A | 1 |
| Pardo, F | 1 |
| Montalto, G | 1 |
| Iapichino, L | 1 |
| Soresi, M | 1 |
| Averna, MR | 1 |
| Iacono, G | 1 |
| Notarbartolo, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proton Pump Inhibitors (PPI) and Fat Absorption in Subjects With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)[NCT03551691] | Phase 2 | 19 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for famotidine and Cystic Fibrosis
| Article | Year |
|---|---|
Do H2 receptor antagonists have a therapeutic role in childhood?
Topics: Adolescent; Child; Child, Preschool; Cimetidine; Cystic Fibrosis; Drug Interactions; Famotidine; Gas | 1994 |
2 trials available for famotidine and Cystic Fibrosis
| Article | Year |
|---|---|
Pharmacokinetics of famotidine in patients with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Biological Availability; Child; Cross-Ove | 1998 |
Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis.
Topics: Adolescent; Celiac Disease; Child; Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Famotidine; F | 1992 |
1 other study available for famotidine and Cystic Fibrosis
| Article | Year |
|---|---|
Challenges and safety of beta-lactam desensitization during extracorporeal membrane oxygenation.
Topics: Acetates; Allergens; Anaphylaxis; Anti-Infective Agents; Antibiotic Prophylaxis; beta-Lactams; Cetir | 2019 |